1.53
0.28 (22.40%)
| Previous Close | 1.25 |
| Open | 1.25 |
| Volume | 4,995,897 |
| Avg. Volume (3M) | 1,517,495 |
| Market Cap | 177,910,992 |
| Price / Sales | 22.16 |
| Price / Book | 0.700 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Operating Margin (TTM) | -2,534.07% |
| Diluted EPS (TTM) | -1.49 |
| Quarterly Revenue Growth (YOY) | -15.40% |
| Total Debt/Equity (MRQ) | 28.89% |
| Current Ratio (MRQ) | 8.81 |
| Operating Cash Flow (TTM) | -123.33 M |
| Levered Free Cash Flow (TTM) | -76.88 M |
| Return on Assets (TTM) | -23.97% |
| Return on Equity (TTM) | -49.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Fate Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.74% |
| % Held by Institutions | 94.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wilshire Advisors Llc | 30 Sep 2025 | 8,486,822 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |